Literature DB >> 498116

Effect of 5-fluorouracil on RNA metabolism in Novikoff hepatoma cells.

J G Cory, J C Breland, G L Carter.   

Abstract

The resistance of a Novikoff hepatoma cell line (N1-S1/FdUrd) to 5-fluorouracil (FUra) was reversed by the inclusion of inosine in the culture medium. As the concentration of inosine in the medium was increased, there was a marked increase in the uptake of [14C]FUra and conversion to nucleotides with a corresponding increase in the incorporation into RNA. While FUra alone had no effect on this resistant cell line, the combination of FUra plus inosine altered the levels of ribose 1-phosphate but not 5-phosphoribosyl 1-pyrophosphate, altered the maturation of precursor ribosomal RNA by blocking the formation of 18S RNA, altered the methylation of the ribosomal RNA, and caused inhibition of the growth of these cells. No evidence was obtained that fluorodeoxyuridine 5'-monophosphate was formed in the N1-S1/FdUrd cells as a result of treatment with FUra plus inosine. In addition, the metabolism of [3H]deoxycytidine in the presence of FUra plus inosine in the intact N1-S1/FdUrd cells did not indicate significant inhibition of thymidylate synthetase as evidenced by the levels of deoxyuridine 5'-monophosphate or conversion to thymidine 5'-monophosphate.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 498116

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Effects of experimental chemoendocrine therapy with a combination of a pure antiestrogen and 5-fluorouracil on human breast cancer cells implanted in nude mice.

Authors:  Y Ogasawara; H Doihara; K Shiroma; Y Kanaya; N Shimizu
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

2.  Correlation between expression of orotate phosphoribosyl transferase and 5-fluorouracil sensitivity, as measured by apoptosis index in colorectal cancer tissue.

Authors:  Ken Kawai; Suguru Watabe; Mitsuhiro Matsuda; Kazuhiro Sakamoto; Toshiki Kamano
Journal:  Int J Gastrointest Cancer       Date:  2005

Review 3.  RNA modifications: a mechanism that modulates gene expression.

Authors:  John Karijolich; Athena Kantartzis; Yi-Tao Yu
Journal:  Methods Mol Biol       Date:  2010

4.  Disruption of p53 in human cancer cells alters the responses to therapeutic agents.

Authors:  F Bunz; P M Hwang; C Torrance; T Waldman; Y Zhang; L Dillehay; J Williams; C Lengauer; K W Kinzler; B Vogelstein
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

5.  Less cytotoxicity to combination therapy of 5-fluorouracil and cisplatin than 5-fluorouracil alone in human colon cancer cell lines.

Authors:  Xiu-Xu Chen; Mao-De Lai; Yong-Liang Zhang; Qiong Huang
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

Review 6.  Physiological concentrations of purines and pyrimidines.

Authors:  T W Traut
Journal:  Mol Cell Biochem       Date:  1994-11-09       Impact factor: 3.396

7.  In vitro splicing of pre-messenger RNA with extracts from 5-fluorouridine-treated cells.

Authors:  J R Patton
Journal:  Biochem J       Date:  1994-01-15       Impact factor: 3.857

8.  5-fluorouracil enhances exosome-dependent accumulation of polyadenylated rRNAs.

Authors:  Feng Fang; Jason Hoskins; J Scott Butler
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

9.  Concurrent allopurinol and 5-fluorouracil: 5-fluoro-2'-deoxyuridylate formation and thymidylate synthase inhibition in rat colon carcinoma and in regenerating rat liver.

Authors:  M Berne; B Gustavsson; O Almersjö; C P Spears; J Waldenström
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

10.  Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influence.

Authors:  Jonathan R Brody; Tomas Hucl; Christina L Costantino; James R Eshleman; Eike Gallmeier; Heng Zhu; Michiel S van der Heijden; Jordan M Winter; Agnieszka K Wikiewicz; Charles J Yeo; Scott E Kern
Journal:  Cancer Res       Date:  2009-01-20       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.